Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
Holding INZY?
Track your performance easily
INZY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.75 - $7.80
Previous Close$2.81
Volume301.54K
Average Volume (3M)261.58K
Market Cap
$175.38M
Enterprise Value$95.70M
Total Cash (Recent Filing)$131.61M
Total Debt (Recent Filing)$46.79M
Price to Earnings (P/E)―
Beta3.01
Next Earnings
Mar 20, 2025EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding64,240,198
10 Day Avg. Volume414,551
30 Day Avg. Volume261,576
Standard Deviation0.30
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.18
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$20.17Price Target Upside638.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Inozyme Pharma News
PremiumCompany Announcements
Inozyme Pharma’s Q3 2024 Financial and Clinical Progress
PremiumPre-Earnings
Is INZY a Buy, Before Earnings?
PremiumCompany Announcements
Inozyme Pharma Reports Promising Results in SEAPORT 1 Trial
PremiumCompany Announcements
Inozyme Pharma Welcomes New Director Erik Harris
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive interim data from the Phase 1 SEAPORT 1 trial at the American Society of Nephrology’s Kidney Week 2024 indicates safety and effectiveness of INZ-701 in increasing pyrophosphate levels in patients with end-stage kidney disease.
Drug DevelopmentINZ-701 has demonstrated the ability to improve PPi levels in deficiency patients and suggests benefits on clinical endpoints.
Financial OutlookThe analyst reiterates a Buy rating and sets a price target based on discounted revenue forecasts for INZ-701, indicating confidence in the drug's future market potential.
Bears Say
Data And Regulatory AlignmentCalciphylaxis specific data and regulatory alignment still need de-risking.
FDA Filing ChallengesThe core of a potential FDA filing in ENPP1 deficiency is expected to come from the randomized ENERGY-3 trial in pediatric ENPP1 patients aged 1-13.
Regulatory RisksClinical trial and regulatory risks are expected to represent the greatest headwind keeping investors at bay.
---
Ownership Overview
2.95% Insiders
16.76% Mutual Funds
60.06% Other Institutional Investors
12.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INZY FAQ
What was Inozyme Pharma’s price range in the past 12 months?
Inozyme Pharma lowest stock price was $2.75 and its highest was $7.79 in the past 12 months.
What is Inozyme Pharma’s market cap?
Currently, no data Available
When is Inozyme Pharma’s upcoming earnings report date?
Inozyme Pharma’s upcoming earnings report date is Mar 20, 2025 which is in 119 days.
How were Inozyme Pharma’s earnings last quarter?
Inozyme Pharma released its earnings results on Nov 05, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.435 by $0.045.
Is Inozyme Pharma overvalued?
According to Wall Street analysts Inozyme Pharma’s price is currently Undervalued.
Does Inozyme Pharma pay dividends?
Inozyme Pharma does not currently pay dividends.
What is Inozyme Pharma’s EPS estimate?
Inozyme Pharma’s EPS estimate is -$0.4.
How many shares outstanding does Inozyme Pharma have?
Inozyme Pharma has 64,240,200 shares outstanding.
What happened to Inozyme Pharma’s price movement after its last earnings report?
Inozyme Pharma reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.435. Following the earnings report the stock price went down -7.919%.
Which hedge fund is a major shareholder of Inozyme Pharma?
Among the largest hedge funds holding Inozyme Pharma’s share is Woodline Partners LP. It holds Inozyme Pharma’s shares valued at 5M.
---
Inozyme Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.17 (638.83% Upside)
$20.17 (638.83% Upside)
Blogger Sentiment
Bullish
INZY Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.80%
12-Months-Change
Fundamentals
Return on Equity
-79.42%
Trailing 12-Months
Asset Growth
-30.31%
Trailing 12-Months
Company Description
Inozyme Pharma
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
---
INZY Stock 12 Month Forecast
Average Price Target
$20.17
▲(638.83% Upside)
Technical Analysis
Best Analysts Covering INZY
1 Year
1 Year Success Rate
13/24 ratings generated profit
1 Year Average Return
+20.24%
reiterated a buy rating 15 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +20.24% per trade.
---